IV Prochlorperazine Beats IV Hydromorphone for Migraine

This article originally appeared here.
Share this content:
IV Prochlorperazine Beats IV Hydromorphone for Migraine
IV Prochlorperazine Beats IV Hydromorphone for Migraine

THURSDAY, Oct. 19, 2017 (HealthDay News) -- Intravenous (IV) hydromorphone is less effective than IV prochlorperazine plus diphenhydramine for acute migraine treatment in the emergency department, according to a study published online Oct. 18 in Neurology.

Benjamin W. Friedman, M.D., from Albert Einstein College of Medicine in Bronx, New York, and colleagues conducted a study involving patients who met international criteria for migraine in two emergency departments in New York City. Participants were randomized in blocks of four and received hydromorphone 1 mg or prochlorperazine 10 mg plus diphenhydramine 25 mg; diphenhydramine was administered to prevent akathisia, which is a frequent adverse effect of IV prochlorperazine.

After enrollment of 127 patients, the trial was halted by the data monitoring committee. The researchers found that the primary outcome of sustained headache relief was achieved by 60 percent of 62 participants in the prochlorperazine arm and by 31 percent of 64 participants in the hydromorphone arm (difference, 28 percent; number needed to treat, 4).

"IV hydromorphone is substantially less effective than IV prochlorperazine for the treatment of acute migraine in the ED and should not be used as first-line therapy," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

CDC Warns of Polio-Like Virus Striking More U.S. Children

CDC Warns of Polio-Like Virus Striking More U.S. ...

127 cases reported in 22 states so far this year with 62 confirmed as acute flaccid myelitis

Harvard: Heart Researcher's Papers Contain Fraudulent Data

Harvard: Heart Researcher's Papers Contain Fraudulent Data

31 scientific publications from the laboratory of Piero Anversa contain falsified and/or fabricated data

Bariatric Sx Cuts Macrovascular Complications in Obesity, T2DM

Bariatric Sx Cuts Macrovascular Complications in Obesity, T2DM

Lower composite incidence of macrovascular events, lower incidence of coronary artery disease at 5 years

is free, fast, and customized just for you!




Already a member?

Sign In Now »